Related Experiment Video
Updated: Aug 10, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease
1Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA.
Plasma homovanillic acid (HVA), but not plasma 3-methoxy-4-hydroxyphenylglycol (MHPG), was substantially increased in 4 patients undergoing hemodialysis, 3 patients with chronic renal failure, and 3 patients receiving carbidopa/levodopa for Parkinson's disease. These conditions should be considered in psychiatric research involving plasma HVA.
Plasma homovanillic acid (HVA), but not plasma 3-methoxy-4-hydroxyphenylglycol (MHPG), was substantially increased in 4 patients undergoing hemodialysis, 3 patients with chronic renal failure, and 3 patients receiving carbidopa/levodopa for Parkinson's disease. These conditions should be considered in psychiatric research involving plasma HVA.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology

